Human immunodeficiency virus inhibition by lysed leukocyte ultrafiltrate
Schmidtmayerová, H.; Chermann, J.C.; Rey, F.; Barré-Sinoussi, F.; Mayer, V.
Acta Virologica 34(3): 263-271
1990
ISSN/ISBN: 0001-723X PMID: 1703392 Document Number: 348132
The in vitro effect of partially purified lysed leukocyte ultrafiltrate (LLU) on LAV 1 strain of the human immunodeficiency virus (HIV) was investigated. Decrease of virus production as a function of LLU concentration was observed while the phenotype of cultured lymphocytes has remained unchanged. We observed the same depletion of helper-inducer T-cells in samples treated with LLU as well as in infected controls. LLU did not influence significantly the growth of cultured lymphocytes. Following the effect of LLU on RNA-dependent DNA polymerase, inhibition of the LAV 1 reverse transcriptase by LLU was observed. This inhibition was shown to be LLU dose-dependent, considering its content of proteins and orcinol-reactive material. Kinetic studies revealed that inhibition is reversible and competitive with the substrate (3HTTP) but not with template-primer (poly rA-oligo dT).
Document emailed within 1 workday
Related Documents
Kline, M.W.; Lewis, D.E.; Hollinger, F.B.; Reuben, J.M.; Hanson, L.C.; Kozinetz, C.A.; Dimitrov, D.H.; Rosenblatt, H.M.; Shearer, W.T. 1994: A comparative study of human immunodeficiency virus culture, polymerase chain reaction and anti-human immunodeficiency virus immunoglobulin A antibody detection in the diagnosis during early infancy of vertically acquired human immunodeficiency virus infection Pediatric Infectious Disease Journal 13(2): 90-94Koyanagi, A.; Humphrey, J.H.; Ntozini, R.; Nathoo, K.; Moulton, L.H.; Iliff, P.; Mutasa, K.; Ruff, A.; Ward, B.; Chidawanyika, H.; Hargrove, J.; Mahomva, A.I.; Majo, F.; Malaba, L.C.; Mbizvo, M.T.; Mzengeza, F.; Ndhlovu, M.; Piwoz, E.; Propper, L.; Rambanepasi, P.; Ruff, A.J.; Tavengwa, N.; Zijenah, L.S.; Zunguza, C.D.; Zvandasara, P. 2011: Morbidity among human immunodeficiency virus-exposed but uninfected, human immunodeficiency virus-infected, and human immunodeficiency virus-unexposed infants in Zimbabwe before availability of highly active antiretroviral therapy Pediatric Infectious Disease Journal 30(1): 45-51
Imanishi, J.; Tanaka, A.; Matsuoka, H. 1984: Inhibition of the multiplication of human herpes virus i by prostaglandin D2 and the synergistic effect of human leukocyte interferon Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales 178(6): 671-674
Lillibridge, J.H.; Liang, B.H.; Kerr, B.M.; Webber, S.; Quart, B.; Shetty, B.V.; Lee, C.A. 1998: Characterization of the selectivity and mechanism of human cytochrome P450 inhibition by the human immunodeficiency virus-protease inhibitor nelfinavir mesylate Drug Metabolism and Disposition: the Biological Fate of Chemicals 26(7): 609-616
Sabidó, M.; Lahuerta, M.; Montoliu, A.; Gonzalez, V.; Hernández, G.; Giardina, F.; Monzón, J.é E.; Pedroza, M.I.; Casabona, J. 2011: Human immunodeficiency virus, sexually transmitted infections, and risk behaviors among clients of sex workers in Guatemala: are they a bridge in human immunodeficiency virus transmission? Sexually Transmitted Diseases 38(8): 735-742
Rasheed, S.; Li, Z.; Xu, D.; Kovacs, A. 1996: Presence of cell-free human immunodeficiency virus in cervicovaginal secretions is independent of viral load in the blood of human immunodeficiency virus-infected women American Journal of Obstetrics and Gynecology 175(1): 122-129
Yusim, K.; Peeters, M.; Pybus, O.G.; Bhattacharya, T.; Delaporte, E.; Mulanga, C.; Muldoon, M.; Theiler, J.; Korber, B. 2001: Using human immunodeficiency virus type 1 sequences to infer historical features of the acquired immune deficiency syndrome epidemic and human immunodeficiency virus evolution Philosophical Transactions of the Royal Society of London. Series B Biological Sciences 356(1410): 855-866
Wen, Y.; Guan, J.; Wu, Z.; Li, L.; Rotheram-Borus, M.Jane.; Lin, C.; Detels, R. 2009: Pharmacy workers' sexually transmitted diseases/human immunodeficiency virus knowledge in Fuzhou, China: implications for human immunodeficiency virus testing, treatment, and prevention strategies Sexually Transmitted Diseases 36(4): 221-226
Clanton, D.J.; Moran, R.A.; McMahon, J.B.; Weislow, O.S.; Buckheit, R.W.; Hollingshead, M.G.; Ciminale, V.; Felber, B.K.; Pavlakis, G.N.; Bader, J.P. 1992: Sulfonic acid dyes: inhibition of the human immunodeficiency virus and mechanism of action Journal of Acquired Immune Deficiency Syndromes 5(8): 771-781
Anonymous 1988: 1988 agent summary statement for human immunodeficiency virus and report on laboratory-acquired infection with human immunodeficiency virus Morbidity and Mortality Weekly Report 37(S-4): 22
Franke, M.F.; Stulac, S.N.; Rugira, I.H.; Rich, M.L.; Bucyibaruta, J.B.; Drobac, P.C.; Iyamungu, G.; Bryant, C.M.; Binagwaho, A.; Farmer, P.E.; Mukherjee, J.S. 2011: High human immunodeficiency virus-free survival of infants born to human immunodeficiency virus-positive mothers in an integrated program to decrease child mortality in rural Rwanda Pediatric Infectious Disease Journal 30(7): 614-616
Kidangazhiayathmana, A. 2011: Is Kerala remaining low prevalent in human immunodeficiency virus by accident? a study of risk factors in acquiring human immunodeficiency virus infection in patients attending Anti-retroviral treatment clinic Indian Journal of Dermatology Venereology and Leprology 77(6): 729
Monteiro, J.P.; Freimanis-Hance, L.; Faria, L.B.; Mussi-Pinhata, M.M.; Korelitz, J.; Vannucchi, H.él.; Queiroz, W.; Succi, R.C.M.; Hazra, R. 2009: Both human immunodeficiency virus-infected and human immunodeficiency virus-exposed, uninfected children living in Brazil, Argentina, and Mexico have similar rates of low concentrations of retinol, beta-carotene, and vitamin e Nutrition Research 29(10): 716-722
Borkowsky, W.; Lawrence, H.S. 1979: Effects of human leukocyte dialysates containing transfer factor in the direct leukocyte migration inhibition (LMI) assay Journal of Immunology 123(4): 1741-1748
Heller, T.; Wallrauch, C.; Lessells, R.J.; Goblirsch, S.; Brunetti, E. 2010: Short course for focused assessment with sonography for human immunodeficiency virus/tuberculosis: preliminary results in a rural setting in South Africa with high prevalence of human immunodeficiency virus and tuberculosis American Journal of Tropical Medicine and Hygiene 82(3): 512-515
Machado, A.A.; Hirsch, I.; Figueiredo, J.F.; Martinez, R.; de Freitas-Silva, G.; Chermann, J.C.; Covas, D.T. 1996: Occurrence of false positives in tests with synthetic peptides for the analysis of antibodies against the human immunodeficiency virus type 2 (HIV-2) in Brazilian patients infected with the human immunodeficiency virus type 1 (HIV-1) Revista da Sociedade Brasileira de Medicina Tropical 29(6): 615-617
Diaz, A.; Ten, A.; Marcos, H.; Gutiérrez, G.; González-García, J.; Moreno, S.; Barrios, A.M.ía.; Arponen, S.; Portillo, Ál.; Serrano, R.; García, M.T.; Pérez, J.é L.; Toledo, J.; Royo, M.C.; González, G.; Izquierdo, A.; Viloria, L.J.; López, I.; Elizalde, L.áz.; Martínez, E.; Castrillejo, D.; Aranguren, R.; Redondo, C.; Diez, M. 2015: Factors determining irregular attendance to follow-up visits among human immunodeficiency virus patients: results of the hospital survey of patients infected with human immunodeficiency virus Enfermedades Infecciosas y Microbiologia Clinica 33(5): 324-330
Segat, L.; Crovella, S. 2012: HLA-G 14bp del/ins genetic variation: association with susceptibility to human immunodeficiency virus-1 vertical transmission but not with human immunodeficiency virus-1 infection through horizontal transmission Tissue Antigens 80(1): 12-13
Otsyula, M.G.; Yee, J.A.; Suleman, M.A.; Marx, P.A.; Jennings, M.B. 1996: Immunoassay for detection of antibodies to simian immunodeficiency virus and human immunodeficiency virus in serum Laboratory Animal Science 46(2): 198-201
Balzarini, J.; Velazquez, S.; San-Felix, A.; Karlsson, A.; Perez-Perez, M.J.; Camarasa, M.J.; De Clercq, E. 1993: Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues Molecular Pharmacology 43(1): 109-114